1. Home
  2. IPA
  3. IPA News

Latest ImmunoPrecise Antibodies Ltd. (IPA) News on August 19, 2025

ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology
IPA

Business Wire

2 months ago

ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology

We're Keeping An Eye On ImmunoPrecise Antibodies' (NASDAQ:IPA) Cash Burn Rate
IPA

Simply Wall St.

2 months ago

We're Keeping An Eye On ImmunoPrecise Antibodies' (NASDAQ:IPA) Cash Burn Rate

AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies
IPA

Business Wire

2 months ago

AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies

ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery
IPA

Business Wire

2 months ago

ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery

ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts
IPA

Business Wire

3 months ago

ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts

ImmunoPrecise Antibodies (IPA) to Present at Maxim Group’s 2025 Virtual Tech Conference
IPA

Business Wire

3 months ago

ImmunoPrecise Antibodies (IPA) to Present at Maxim Group’s 2025 Virtual Tech Conference

IPA’s LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed
IPA

Business Wire

3 months ago

IPA’s LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed

ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods
IPA

Business Wire

4 months ago

ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods

ImmunoPrecise Antibodies Third Quarter 2025 Earnings: CA$0.66 loss per share (vs CA$0.11 loss in 3Q 2024)
IPA

Simply Wall St.

5 months ago

ImmunoPrecise Antibodies Third Quarter 2025 Earnings: CA$0.66 loss per share (vs CA$0.11 loss in 3Q 2024)

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025
IPA

Business Wire

5 months ago

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025

Positive Signs As Multiple Insiders Buy ImmunoPrecise Antibodies Stock
IPA

Simply Wall St.

5 months ago

Positive Signs As Multiple Insiders Buy ImmunoPrecise Antibodies Stock

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.
IPA

Business Wire

5 months ago

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.

IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025
IPA

Business Wire

5 months ago

IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025
IPA

Business Wire

5 months ago

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025

IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy
IPA

Business Wire

6 months ago

IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy

ImmunoPrecise Antibodies Announces Key Leadership Changes
IPA

Business Wire

6 months ago

ImmunoPrecise Antibodies Announces Key Leadership Changes

ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period
IPA

Business Wire

6 months ago

ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period

ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture
IPA

Business Wire

7 months ago

ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture

ImmunoPrecise Antibodies develops new class of GLP-1 therapies through AI
IPA

TipRanks

7 months ago

ImmunoPrecise Antibodies develops new class of GLP-1 therapies through AI

IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment
IPA

Business Wire

7 months ago

IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment

ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation
IPA

Business Wire

7 months ago

ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation

ImmunoPrecise Antibodies announces resignation of CFO
IPA

TipRanks

8 months ago

ImmunoPrecise Antibodies announces resignation of CFO

IPA Announces Resignation of Chief Financial Officer
IPA

Business Wire

8 months ago

IPA Announces Resignation of Chief Financial Officer

ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases
IPA

Business Wire

8 months ago

ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases

IPA

ACCESSWIRE

8 months ago

IPA to Present at The Microcap Conference 2025

IPA to Present at The Microcap Conference 2025
IPA

Business Wire

8 months ago

IPA to Present at The Microcap Conference 2025

ImmunoPrecise Antibodies Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
IPA

Simply Wall St.

8 months ago

ImmunoPrecise Antibodies Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025
IPA

Business Wire

8 months ago

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025

IPA to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
IPA

Business Wire

8 months ago

IPA to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024
IPA

Business Wire

9 months ago

IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024

IPA

ACCESSWIRE

9 months ago

DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies
IPA

Business Wire

9 months ago

$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies

ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation
IPA

Business Wire

9 months ago

ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation

ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology
IPA

Business Wire

10 months ago

ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology

ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024
IPA

Business Wire

10 months ago

ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024

ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design
IPA

Business Wire

10 months ago

ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design

ImmunoPrecise Antibodies Ltd (IPA) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amid ...
IPA

GuruFocus.com

10 months ago

ImmunoPrecise Antibodies Ltd (IPA) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amid ...

ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus
IPA

Business Wire

a year ago

ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus

ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments
IPA

Business Wire

a year ago

ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025
IPA

Business Wire

a year ago

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025

Earnings To Watch: ImmunoPrecise Antibodies Ltd (IPA) Reports Q1 2025 Result
IPA

GuruFocus.com

a year ago

Earnings To Watch: ImmunoPrecise Antibodies Ltd (IPA) Reports Q1 2025 Result

IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024
IPA

Business Wire

a year ago

IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024

ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
IPA

Business Wire

a year ago

ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York

ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements
IPA

Business Wire

a year ago

ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements

ImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology
IPA

Business Wire

a year ago

ImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024
IPA

Business Wire

a year ago

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024

ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024
IPA

Business Wire

a year ago

ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024

ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures
IPA

Business Wire

a year ago

ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024
IPA

Business Wire

a year ago

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024

ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer
IPA

Business Wire

a year ago

ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer

IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™
IPA

Business Wire

a year ago

IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™

ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology
IPA

Business Wire

a year ago

ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology

BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery
IPA

Business Wire

a year ago

BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery

IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)
IPA

Business Wire

a year ago

IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)

Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results
IPA

ACCESSWIRE

a year ago

Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results

ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments
IPA

ACCESSWIRE

a year ago

ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments

InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
IPA

Business Wire

a year ago

InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications

IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
IPA

Business Wire

a year ago

IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments

IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*
IPA

Business Wire

a year ago

IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*

ImmunoPrecise Antibodies (NASDAQ:IPA) Subsidiary BioStrand Introduces Breakthrough AI Model In Life Sciences, Harnessing LLM Stacking And HYFT Technology
IPA

ACCESSWIRE

a year ago

ImmunoPrecise Antibodies (NASDAQ:IPA) Subsidiary BioStrand Introduces Breakthrough AI Model In Life Sciences, Harnessing LLM Stacking And HYFT Technology

IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology
IPA

Business Wire

a year ago

IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024
IPA

Business Wire

a year ago

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024

ImmunoPrecise Antibodies (NASDAQ:IPA) Is Changing How We Look At The Complex World Of Antibody Discovery
IPA

ACCESSWIRE

2 years ago

ImmunoPrecise Antibodies (NASDAQ:IPA) Is Changing How We Look At The Complex World Of Antibody Discovery

Invesco Closed-End Funds Declare Dividends
IPA

PR Newswire

2 years ago

Invesco Closed-End Funds Declare Dividends

Western New England Bancorp's (NASDAQ:WNEB) Dividend Will Be $0.07
IPA

Simply Wall St.

2 years ago

Western New England Bancorp's (NASDAQ:WNEB) Dividend Will Be $0.07

JOHN HANCOCK CLOSED-END FUNDS RELEASE EARNINGS DATA
IPA

PR Newswire

2 years ago

JOHN HANCOCK CLOSED-END FUNDS RELEASE EARNINGS DATA

Valens Semiconductor Enables Unprecedented, Resilient Surround View Systems for Long Vehicles, with its New VA700R Series, Capable of 40-Meter Multi-Gig Connectivity
IPA

PR Newswire

2 years ago

Valens Semiconductor Enables Unprecedented, Resilient Surround View Systems for Long Vehicles, with its New VA700R Series, Capable of 40-Meter Multi-Gig Connectivity

DHI Group, Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024
IPA

Business Wire

2 years ago

DHI Group, Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024

A Look At The Intrinsic Value Of FAT Brands Inc. (NASDAQ:FAT)
IPA

Simply Wall St.

2 years ago

A Look At The Intrinsic Value Of FAT Brands Inc. (NASDAQ:FAT)

UEI Announces QuickSet® Software Expansion for Better Entertainment and Increased Engagement through Personalization
IPA

Business Wire

2 years ago

UEI Announces QuickSet® Software Expansion for Better Entertainment and Increased Engagement through Personalization

3 Natural Food Stocks in Focus on Impressive Industry Trends
IPA

Zacks

2 years ago

3 Natural Food Stocks in Focus on Impressive Industry Trends

ImmunoPrecise Antibodies Reports A 19.9% Revenue Increase As It Launches The Next Phase Of LENSai Portal And SaaS Platforms
IPA

ACCESSWIRE

2 years ago

ImmunoPrecise Antibodies Reports A 19.9% Revenue Increase As It Launches The Next Phase Of LENSai Portal And SaaS Platforms

Globalink Investment Inc. Announces Extension of the Deadline to Complete a Business Combination to February 9, 2024
IPA

GlobeNewswire

2 years ago

Globalink Investment Inc. Announces Extension of the Deadline to Complete a Business Combination to February 9, 2024

Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
IPA

GlobeNewswire

2 years ago

Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea

Billionaire Louis Bacon’s 15 Long-Term Stock Picks
IPA

Insider Monkey

2 years ago

Billionaire Louis Bacon’s 15 Long-Term Stock Picks

Despite Fast-paced Momentum, TransAct Technologies Incorporated (TACT) Is Still a Bargain Stock
IPA

Zacks

2 years ago

Despite Fast-paced Momentum, TransAct Technologies Incorporated (TACT) Is Still a Bargain Stock

Estimating The Fair Value Of Niu Technologies (NASDAQ:NIU)
IPA

Simply Wall St.

2 years ago

Estimating The Fair Value Of Niu Technologies (NASDAQ:NIU)

Alphavest Acquisition Corp Announces Adjournment of Extraordinary General Meeting of Shareholders
IPA

GlobeNewswire

2 years ago

Alphavest Acquisition Corp Announces Adjournment of Extraordinary General Meeting of Shareholders

Intuitive Machines IM-1 Lunar Mission Launch Update
IPA

GlobeNewswire

2 years ago

Intuitive Machines IM-1 Lunar Mission Launch Update

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q2 2024 Earnings Call Transcript
IPA

Insider Monkey

2 years ago

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q2 2024 Earnings Call Transcript

reAlpha to Acquire United Software Group to Boost AI Capabilities
IPA

Exec Edge

2 years ago

reAlpha to Acquire United Software Group to Boost AI Capabilities

IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024*
IPA

Business Wire

2 years ago

IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024*

Eos Energy and Pine Gate Renewables Announce Partnership Expansion
IPA

GlobeNewswire

2 years ago

Eos Energy and Pine Gate Renewables Announce Partnership Expansion

Northern Dynasty Announces US$15 Million Convertible Notes Offering and Up To CAD$3.4 Million Private Placement
IPA

ACCESSWIRE

2 years ago

Northern Dynasty Announces US$15 Million Convertible Notes Offering and Up To CAD$3.4 Million Private Placement

Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
IPA

GlobeNewswire

2 years ago

Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting

IPA Announces Closing of $1.265 Million Public Offering of Common Shares
IPA

Business Wire

2 years ago

IPA Announces Closing of $1.265 Million Public Offering of Common Shares

Calculating The Fair Value Of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
IPA

Simply Wall St.

2 years ago

Calculating The Fair Value Of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

ImmunoPrecise Antibodies Welcomes Mitch Levine To Its Board Of Directors, To Announce Quarterly Results On December 14
IPA

ACCESSWIRE

2 years ago

ImmunoPrecise Antibodies Welcomes Mitch Levine To Its Board Of Directors, To Announce Quarterly Results On December 14

Li-Cycle Comments on Process to Evaluate Financing and Strategic Alternatives
IPA

Business Wire

2 years ago

Li-Cycle Comments on Process to Evaluate Financing and Strategic Alternatives

IPA Announces Pricing of $1.1 Million Public Offering of Common Shares
IPA

Business Wire

2 years ago

IPA Announces Pricing of $1.1 Million Public Offering of Common Shares

IPA Announces Proposed Public Offering of Common Shares
IPA

Business Wire

2 years ago

IPA Announces Proposed Public Offering of Common Shares

Pixelworks Empowers OnePlus 12 Smartphone to Deliver a Fully Immersive Gaming Experience
IPA

PR Newswire

2 years ago

Pixelworks Empowers OnePlus 12 Smartphone to Deliver a Fully Immersive Gaming Experience

3 Underperforming Bank Stocks You Better Not Be Buying
IPA

InvestorPlace

2 years ago

3 Underperforming Bank Stocks You Better Not Be Buying

Matterport Signs Multi-Year Partnership with Vacasa to Provide Digital Twins for International Portfolio of Vacation Homes
IPA

GlobeNewswire

2 years ago

Matterport Signs Multi-Year Partnership with Vacasa to Provide Digital Twins for International Portfolio of Vacation Homes

GeneDx to Participate in 6th Annual Evercore ISI HealthCONx Conference
IPA

GlobeNewswire

2 years ago

GeneDx to Participate in 6th Annual Evercore ISI HealthCONx Conference

ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call
IPA

Business Wire

2 years ago

ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call

Inventiva reports 2023 Third Quarter Financial Information¹
IPA

GlobeNewswire

2 years ago

Inventiva reports 2023 Third Quarter Financial Information¹

IPA

GuruFocus.com

2 years ago

SKYX Platforms Corp. Reports Record Q3 Revenue of $21.6 Million Amidst Strategic Expansion

IPA

Business Wire

2 years ago

Danimer Scientific Announces Third Quarter 2023 Results

Sonida Senior Living, Inc. Announces Third Quarter 2023 Results
IPA

Business Wire

2 years ago

Sonida Senior Living, Inc. Announces Third Quarter 2023 Results

Share on Social Networks: